OncoMatch

OncoMatch/Clinical Trials/NCT06520098

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Is NCT06520098 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Venetoclax and Ibrutinib, Acalabrutinib, Zanubrutinib for chronic lymphocytic leukemia.

Phase 2RecruitingVA Office of Research and DevelopmentNCT06520098Data as of May 2026

Treatment: Venetoclax · Ibrutinib, Acalabrutinib, Zanubrutinib — People who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are often treated with ibrutinib, acalabrutinib, or zanubrutinib. These are pills that are taken by mouth. This type of pill is called "Bruton Tyrosine Kinase Inhibitor" or BTKi. Another treatment for CLL/SLL is a different pill called venetoclax. The purpose of this study is to compare continuing the current treatment with BTKi alone, as long as it is working, to another arm of treatment which adds venetoclax to the current treatment (BTKi), for one year. After one year, both pills in this arm of treatment would be stopped and the participants will be closely monitored.

Check if I qualify

Extracted eligibility criteria

Cancer type

Chronic Lymphocytic Leukemia

Non-Hodgkin Lymphoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Must have received: BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib) — currently receiving for at least six months

Patients must be currently receiving CLL/SLL directed therapy with a BTKi (i.e., ibrutinib, acalabrutinib, zanubrutinib) for at least six months.

Cannot have received: BTK inhibitor + venetoclax combination

Patients must not have received the combination of BTKi + venetoclax previously.

Lab requirements

Blood counts

Absolute Neutrophil Count (ANC) 1,000/mm3 except if due to bone marrow involvement; Platelet Count (untransfused) 30,000/mm3 except if due to bone marrow involvement

Kidney function

Calc. Creatinine Clearance 40 mL/min (by Cockcroft-Gault)

Liver function

Bilirubin 1.5 x upper limit of normal (ULN) except if due to liver involvement, hemolysis, or Gilbert's disease; AST / ALT 2.5 x upper limit of normal (ULN) except if due to liver involvement

Absolute Neutrophil Count (ANC) 1,000/mm3 except if due to bone marrow involvement; Platelet Count (untransfused) 30,000/mm3 except if due to bone marrow involvement; Calc. Creatinine Clearance 40 mL/min (by Cockcroft-Gault); Bilirubin 1.5 x upper limit of normal (ULN) except if due to liver involvement, hemolysis, or Gilbert's disease; AST / ALT 2.5 x upper limit of normal (ULN) except if due to liver involvement

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • San Francisco VA Medical Center, San Francisco, CA · San Francisco, California
  • Kansas City VA Medical Center, Kansas City, MO · Kansas City, Missouri
  • Durham VA Medical Center, Durham, NC · Durham, North Carolina
  • VA Puget Sound Health Care System Seattle Division, Seattle, WA · Seattle, Washington

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify